Celcuity (CELC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on the stock and has a $27.00 price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Swayampakula Ramakanth’s rating is based on several promising developments in Celcuity’s clinical trials and financial stability. The company is set to present significant data from its Phase 3 VIKTORIA-1 Study in late 2025, which could potentially lead to a new drug application if the results are favorable. The study focuses on treating HR+/HER2- advanced breast cancer, and previous trials have shown promising progression-free survival rates.
Additionally, Celcuity is advancing its pipeline with the imminent dosing in the Phase 3 VIKTORIA-2 Study and upcoming data from a prostate cancer study. Financially, despite reporting no revenues and a net loss in the first quarter of 2025, the company holds a strong cash position of $206 million, expected to support operations through 2026. These factors collectively contribute to the Buy rating, reflecting optimism in the company’s potential for future growth and success in its clinical endeavors.
According to TipRanks, Ramakanth is an analyst with an average return of -1.1% and a 34.60% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, RenovoRx, and Delcath Systems.
In another report released on May 16, Leerink Partners also maintained a Buy rating on the stock with a $28.00 price target.